BioSpace News Archive

Guardant360 ® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Guardant Health blood test identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted treatment with RYBREVANT™ after progressing on or after platinum-based chemotherapy

- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho’s new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Antibody test targets the S1 spike protein and is calibrated to the WHO

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China , today announced changes in its board of directors.

Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the employee’s commencement of employment with Sesen Bio.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announced today that due to the unfortunate continued travel restrictions and inability to cross the US/Canadian border since the COVID-19 pandemic began, including the inability to predict when travel restrictions will end,

Relay Medical Corp. reports on completing the integration of its newly acquired Cybeats Technologies, and commences commercial scale-out.